For clinicians seeking to provide the most effective HIV management, choosing ART for treatment-experienced patients with resistance-associated mutations may present a significant challenge. If a patient has developed resistance to medications from one or more classes of ART, which agents or combinations of agents are most likely to provide adequate treatment? What place should newer antiretroviral drugs have in the treatment armamentarium?
These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this issue of eHIV Review.
Associate Professor of Medicine, Division of Allergy and Infectious Diseases
University of Washington
Boston Medical Center
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: September 27, 2022
Expiration date: September 26, 2024